Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:vandetanib
go back to main search page
Accession:CHEBI:49960 term browser browse the term
Definition:A quinazoline that is 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline bearing additional methoxy and 4-bromo-2-fluorophenylamino substituents at positions 6 and 4 respectively. Used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
Synonyms:exact_synonym: N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
 related_synonym: 4-BROMO-2-FLUORO-N-[(4E)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLIN-4(1H)-YLIDENE]ANILINE;   Formula=C22H24BrFN4O2;   InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27);   InChIKey=UHTHHESEBZOYNR-UHFFFAOYSA-N;   SMILES=COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1;   ZD 6474;   ZD6474;   Zactima;   caprelsa
 alt_id: CHEBI:38942;   CHEBI:49959;   MESH:C452423
 xref: CAS:443913-73-3;   DrugBank:DB08764;   Drug_Central:4178;   KEGG:D06407;   LINCS:LSM-1199
 xref_mesh: MESH:C452423
 xref: PDBeChem:ZD6;   PMID:12684431;   PMID:14760102;   PMID:15305185;   PMID:15367698;   PMID:15596048;   PMID:15604279;   PMID:15623642;   PMID:15623658;   PMID:15928657;   PMID:16140331;   PMID:16179094;   PMID:16299247;   PMID:16361567;   PMID:16377413;   PMID:16688779;   PMID:16783964;   PMID:16843002;   PMID:17136225;   PMID:17393165;   PMID:17409986;   PMID:17631646;   PMID:17878479;   PMID:17912240;   PMID:18228115;   PMID:18698025;   PMID:18936474;   PMID:19002384;   PMID:19088171;   PMID:19211364;   PMID:19220256;   PMID:19332730;   PMID:19349511;   PMID:19394692;   PMID:19512898;   PMID:19622715;   PMID:19687425;   PMID:19881951;   PMID:19883226;   PMID:19946413;   PMID:20371720;   PMID:21046425;   PMID:21353546;   PMID:21718364;   PMID:22075979;   PMID:22158569;   PMID:22169262;   PMID:22184381;   PMID:22245891;   PMID:22307735;   PMID:22343387;   PMID:22346266;   PMID:22370318;   PMID:22500115;   PMID:22505191;   PMID:22608542;   PMID:22611027;   PMID:22633931;   PMID:22665903;   PMID:22667325;   PMID:22701615;   PMID:22781612;   PMID:22830347;   PMID:22898678;   PMID:22938056;   Patent:US2006135486;   Patent:US2008032989;   Patent:US2008199480;   Patent:WO2005115145;   Patent:WO2006005915;   Patent:WO2007036713;   Patent:WO2008001101;   Patent:WO2008007113;   Patent:WO2009024825;   Patent:WO2012055015;   Reaxys:9161676;   Wikipedia:Vandetanib


show annotations for term's descendants           Sort by:
vandetanib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adm adrenomedullin increases expression
increases expression 		ISO vandetanib results in increased expression of ADM mRNA
vandetanib increases expression of ADM mRNA in gastric tumors of human cells in mouse model		 CTD
RGD		 PMID:16052530 PMID:16052530 RGD:153344579 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation
multiple interactions		 ISO vandetanib results in decreased phosphorylation of AKT1 protein
INS protein inhibits the reaction [vandetanib results in decreased phosphorylation of AKT1 protein]		 CTD PMID:23799852 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Angptl4 angiopoietin-like 4 increases expression ISO vandetanib results in increased expression of ANGPTL4 mRNA CTD PMID:16052530 NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519 		JBrowse link
G Bnip3l BCL2 interacting protein 3 like increases expression ISO vandetanib results in increased expression of BNIP3L mRNA CTD PMID:16052530 NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803 		JBrowse link
G Calb1 calbindin 1 increases expression ISO vandetanib results in increased expression of CALB1 mRNA CTD PMID:16052530 NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [3-methyladenine co-treated with vandetanib] results in increased activity of CASP3 protein; [Chloroquine co-treated with vandetanib] results in increased activity of CASP3 protein CTD PMID:23799852 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 multiple interactions ISO [3-methyladenine co-treated with vandetanib] results in increased activity of CASP9 protein; [Chloroquine co-treated with vandetanib] results in increased activity of CASP9 protein CTD PMID:23799852 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Col4a3 collagen type IV alpha 3 chain increases expression ISO vandetanib results in increased expression of COL4A3 mRNA CTD PMID:16052530 NCBI chr 9:83,875,849...84,004,955
Ensembl chr 9:83,875,561...84,001,895 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 affects metabolic processing
multiple interactions		 ISO CYP3A4 protein alternative form affects the metabolism of vandetanib
Ketoconazole affects the reaction [CYP3A4 protein alternative form affects the metabolism of vandetanib]		 CTD PMID:34648813 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Dusp1 dual specificity phosphatase 1 increases expression ISO vandetanib results in increased expression of DUSP1 mRNA CTD PMID:16052530 NCBI chr10:16,680,478...16,683,275 JBrowse link
G Egfr epidermal growth factor receptor affects response to substance
decreases activity
decreases phosphorylation		 ISO EGFR affects the susceptibility to vandetanib
vandetanib results in decreased activity of EGFR protein
vandetanib results in decreased phosphorylation of EGFR protein		 CTD PMID:15596048 PMID:15604279 PMID:21350000 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 decreases phosphorylation ISO vandetanib results in decreased phosphorylation of EIF4EBP1 protein CTD PMID:23799852 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984 		JBrowse link
G Eno2 enolase 2 increases expression ISO vandetanib results in increased expression of ENO2 mRNA CTD PMID:16052530 NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980 		JBrowse link
G Fam13a family with sequence similarity 13, member A increases expression ISO vandetanib results in increased expression of FAM13A mRNA CTD PMID:16052530 NCBI chr 4:88,056,521...88,155,782
Ensembl chr 4:88,058,403...88,155,860 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO vandetanib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G H1f2 H1.2 linker histone, cluster member increases expression ISO vandetanib results in increased expression of H1-2 mRNA CTD PMID:16052530 NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635 		JBrowse link
G Hilpda hypoxia inducible lipid droplet-associated increases expression ISO vandetanib results in increased expression of HILPDA mRNA CTD PMID:16052530 NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression ISO vandetanib results in increased expression of IGFBP1 mRNA CTD PMID:16052530 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 increases expression
increases expression 		ISO vandetanib results in increased expression of IGFBP3 mRNA
vandetanib increases expression of IGFBP-3 mRNA in gastric tumors of human cells in mouse model		 CTD
RGD		 PMID:16052530 PMID:16052530 RGD:153344579 NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083 		JBrowse link
G Ins2 insulin 2 multiple interactions ISO INS protein inhibits the reaction [vandetanib results in decreased phosphorylation of AKT1 protein]; INS protein inhibits the reaction [vandetanib results in decreased phosphorylation of RPS6 protein] CTD PMID:23799852 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775 		JBrowse link
G Insig1 insulin induced gene 1 increases expression ISO vandetanib results in increased expression of INSIG1 mRNA CTD PMID:16052530 NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952 		JBrowse link
G Insig2 insulin induced gene 2 increases expression ISO vandetanib results in increased expression of INSIG2 mRNA CTD PMID:16052530 NCBI chr13:32,472,390...32,500,139
Ensembl chr13:32,473,742...32,494,923 		JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 affects binding
multiple interactions
decreases expression		 ISO vandetanib binds to KCNH2 protein
Brefeldin A promotes the reaction [vandetanib results in decreased expression of KCNH2 protein modified form]; N-butanoylsphingosine inhibits the reaction [vandetanib results in decreased expression of KCNH2 protein modified form]; vandetanib results in decreased expression of and results in decreased activity of KCNH2 protein		 CTD PMID:29630634 PMID:35680041 NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008 		JBrowse link
G Kdm3a lysine demethylase 3A increases expression ISO vandetanib results in increased expression of KDM3A mRNA CTD PMID:16052530 NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073 		JBrowse link
G Msh3 mutS homolog 3 decreases expression ISO vandetanib results in decreased expression of MSH3 mRNA CTD PMID:16052530 NCBI chr 2:23,444,326...23,585,777 JBrowse link
G Muc1 mucin 1, cell surface associated increases expression ISO vandetanib results in increased expression of MUC1 mRNA CTD PMID:16052530 NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733 		JBrowse link
G Ndrg1 N-myc downstream regulated 1 increases expression ISO vandetanib results in increased expression of NDRG1 mRNA CTD PMID:16052530 NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880 		JBrowse link
G Pgk1 phosphoglycerate kinase 1 increases expression ISO vandetanib results in increased expression of PGK1 mRNA CTD PMID:16052530 NCBI chr  X:71,271,454...71,287,429
Ensembl chr  X:71,271,440...71,287,418 		JBrowse link
G Plod2 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 increases expression ISO vandetanib results in increased expression of PLOD2 mRNA CTD PMID:16052530 NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255 		JBrowse link
G Ptma prothymosin alpha decreases expression ISO vandetanib results in decreased expression of PTMA mRNA CTD PMID:16052530 NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333 		JBrowse link
G Ret ret proto-oncogene decreases phosphorylation ISO vandetanib results in decreased phosphorylation of RET protein CTD PMID:17431108 NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176 		JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions		 ISO vandetanib results in decreased phosphorylation of RPS6 protein
INS protein inhibits the reaction [vandetanib results in decreased phosphorylation of RPS6 protein]		 CTD PMID:23799852 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602 		JBrowse link
G Scd stearoyl-CoA desaturase increases expression ISO vandetanib results in increased expression of SCD mRNA CTD PMID:16052530 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Slc2a3 solute carrier family 2 member 3 increases expression ISO vandetanib results in increased expression of SLC2A3 mRNA CTD PMID:16052530 NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472 		JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO vandetanib results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228 		JBrowse link
G Tsc22d3 TSC22 domain family, member 3 increases expression ISO vandetanib results in increased expression of TSC22D3 mRNA CTD PMID:16052530 NCBI chr  X:104,217,898...104,277,886
Ensembl chr  X:104,217,925...104,276,861 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19874
    role 19844
      application 19689
        pharmaceutical 19525
          drug 19525
            antineoplastic agent 17817
              vandetanib 36
                linkable vandetanib analogue 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19874
    subatomic particle 19872
      composite particle 19872
        hadron 19872
          baryon 19872
            nucleon 19872
              atomic nucleus 19872
                atom 19872
                  main group element atom 19811
                    main group molecular entity 19811
                      s-block molecular entity 19647
                        hydrogen molecular entity 19628
                          hydrides 19139
                            inorganic hydride 18156
                              pnictogen hydride 18146
                                nitrogen hydride 18059
                                  azane 17866
                                    ammonia 17865
                                      organic amino compound 17865
                                        secondary amino compound 6953
                                          secondary amine 1847
                                            vandetanib 36
                                              linkable vandetanib analogue 0
paths to the root